TUCSON, Ariz. and PALO ALTO, Calif., Dec. 16, 2020 — Avery Therapeutics, a Tucson-based company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, and I Peace, Inc., a Palo Alto-based biotech startup developing, mass-manufacturing, and commercializing Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs), announced a service agreement to advance cell therapy for heart failure. Under the agreement, I Peace will generate and supply GMP-grade induced pluripotent stem cells (iPSCs) and related services to Avery Therapeutics. Avery Therapeutics will use the iPSCs to derive cells used in the manufacturing of MyCardia™. [Read more…]
CILOA creates its new GMP-compliant production unit
The French biotech company Ciloa creates its new GMP-compliant production unit as part of the development of a new generation of exosome-based vaccines and therapeutic vectors.
-
This first production unit is designed to meet GMP (Good Manufacturing Practices) standards, thereby ensuring the autonomy of Ciloa in the development of its biomanufacturing infrastructure and in the progress towards its future clinical studies.
-
The technology developed by Ciloa uses exosomes, small nanovesicles capable of transporting therapeutic proteins, for the development of a new generation of treatments and vaccines, notably in Covid-19 disease.
Patent (IP) Analysis for the Global Induced Pluripotent Stem Cell Industry
Induced pluripotent stem cells (iPSCs) are a unique type of stem cell that can be developed from somatic cells by inserting genes that transform them into an embryonic-like state. These artificially-developed pluripotent cells can proliferate and self-renew indefinitely in vitro, as well as differentiate into different types of specialized cells. [Read more…]
Performance Cell Manufacturing, CDMO Division of VetStem Biopharma
San Diego based Performance Cell Manufacturing is the newly formed CDMO division of VetStem Biopharma
Poway, California, December 8, 2020. – Performance Cell Manufacturing (PCM), is the newly formed contract development and manufacturing organization (CDMO) division of VetStem Biopharma.
PCM was born from VetStem’s 15 years of experience with cGMP compliant cell therapy product development and manufacturing. PCM provides cell therapy development and cGMP contract manufacturing for companies for FDA phase 1 and phase 2 clinical trials. [Read more…]
Ushering in the Era of CAR-T: Kymriah, Yescarta, and Tecartus
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” [Read more…]
- « Previous Page
- 1
- …
- 176
- 177
- 178
- 179
- 180
- …
- 336
- Next Page »